(Q33581197)

28 July 2017

1 reference

title

An introduction to Markov modelling for economic evaluation (English)

1 reference

28 July 2017

Briggs A

1

1 reference

28 July 2017

Sculpher M

series ordinal

2

1 reference

28 July 2017

publication date

1 April 1998

1 reference

28 July 2017

number of pages

13

1 reference

inferred from page(s)

published in

PharmacoEconomics

1 reference

28 July 2017

volume

13

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

397-409

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199813040-00003

28 July 2017

exact match

0 references

cites work

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

12 December 2020

Modelling in economic evaluation: an unavoidable fact of life

1 reference

12 December 2020

Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction

1 reference

12 December 2020

Discounting and health benefits: another perspective

1 reference

12 December 2020

Timing and timeliness in medical care evaluation

1 reference

12 December 2020

Deciphering death: a commentary on Gompertz (1825) 'On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies'.

1 reference

12 December 2020

Determining transition probabilities: confusion and suggestions

1 reference

12 December 2020

Using Economics to Prioritize Research: A Case Study of Randomized Trials for the Prevention of Hip Fractures Due to Osteoporosis

1 reference

12 December 2020

The iterative use of economic evaluation as part of the process of health technology assessment

1 reference

12 December 2020

A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions

1 reference

12 December 2020

Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project.

1 reference

12 December 2020

Why we need observational studies to evaluate the effectiveness of health care

1 reference

12 December 2020

On the Discounting of Gained life-Years in Cost-Effectiveness Analysis

1 reference

12 December 2020

Strategic use of pharmacoeconomic research in early drug development and global pricing

1 reference

12 December 2020

Markov models in medical decision making: a practical guide.

1 reference

12 December 2020

Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy

1 reference

12 December 2020

Static and dynamic models of interdisease competition: past and projected mortality from amyotrophic lateral sclerosis and multiple sclerosis

1 reference

12 December 2020

Discounting and health benefits

1 reference

12 December 2020

A model for evaluating the cost-effectiveness of cholesterol-lowering treatment

1 reference

12 December 2020

Management of asymptomatic popliteal aneurysms: the use of a Markov decision tree to determine the criteria for a conservative approach

1 reference

12 December 2020

Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

1 reference

12 December 2020

Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.

1 reference

12 December 2020

10.2165/00019053-199813040-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

28 July 2017

1018855315

0 references

1 reference